nach oben

Erschienen in:

10.05.2019 | EM - REVIEW

Scleroderma renal crisis: a review for emergency physicians

Erschienen in: Internal and Emergency Medicine | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Scleroderma renal crisis (SRC) remains a high-risk clinical presentation, and many patients require emergency department (ED) management for complications and stabilization. This narrative review provides an evidence-based summary of the current data for the emergency medicine evaluation and management of SRC. While SRC remains a rare clinical presentation, surveillance data suggest an overall incidence between 4 and 6% of patients with scleroderma. The diagnostic criteria for SRC include a new onset blood pressure > 150/85 mm Hg OR increase ≥ 20 mm Hg from baseline systolic blood pressure, along with a decline in renal function, defined as an increase serum creatinine of ≥ 10% and supportive features. There are many risk factors for SRC, including diffuse and rapidly progressive skin thickening, palpable tendon friction rubs, and new anemia or cardiac events. Critical patients should be evaluated in the resuscitation bay, and consultation with the nephrology team for appropriate patients improves patient outcomes.

Pope J, Harding S, Khimdas S, Bonner A, Canadian Scleroderma Research G, Baron M (2012) Agreement with guidelines from a large database for management of systemic sclerosis: results from the Canadian Scleroderma Research Group. J Rheumatol 39(3):524–531. https://doi.org/10.3899/jrheum.110121 CrossRef

Sapadin AN, Fleischmajer R (2002) Treatment of scleroderma. Arch Dermatol 138(1):99–105CrossRefPubMed

Abraham DJ, Krieg T, Distler J, Distler O (2009) Overview of pathogenesis of systemic sclerosis. Rheumatology (Oxford) 48(Suppl 3):iii3–7. https://doi.org/10.1093/rheumatology/ken481

Penn H, Howie AJ, Kingdon EJ, Bunn CC, Stratton RJ, Black CM, Burns A, Denton CP (2007) Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM 100(8):485–494. https://doi.org/10.1093/qjmed/hcm052 CrossRefPubMed

Denton CP, Lapadula G, Mouthon L, Muller-Ladner U (2009) Renal complications and scleroderma renal crisis. Rheumatology (Oxford) 48 Suppl 3:iii32–35. https://doi.org/10.1093/rheumatology/ken483

Akoglu H, Atilgan GK, Ozturk R, Yenigun EC, Gonul II, Odabas AR (2009) A "silent" course of normotensive scleroderma renal crisis: case report and review of the literature. Rheumatol Int 29(10):1223–1229. https://doi.org/10.1007/s00296-008-0807-1 CrossRefPubMed

Adnan ZA (2008) Diagnosis and treatment of scleroderma. Acta Med Indones 40(2):109–112PubMed

Moore SC, Desantis ER (2008) Treatment of complications associated with systemic sclerosis. Am J Health Syst Pharm 65(4):315–321. https://doi.org/10.2146/ajhp070024 CrossRefPubMed

Hudson M, Baron M, Tatibouet S, Furst DE, Khanna D, International Scleroderma Renal Crisis Study I (2014) Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis-results from the International Scleroderma Renal Crisis Survey. Semin Arthritis Rheum 43(5):666–672. https://doi.org/10.1016/j.semarthrit.2013.09.008 CrossRef

10.

Highland KB, Silver RM (2005) New developments in scleroderma interstitial lung disease. Curr Opin Rheumatol 17(6):737–745CrossRefPubMed

11.

Walker UA, Tyndall A, Czirjak L, Denton C, Farge-Bancel D, Kowal-Bielecka O, Muller-Ladner U, Bocelli-Tyndall C, Matucci-Cerinic M (2007) Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma trials and research group database. Ann Rheum Dis 66(6):754–763. https://doi.org/10.1136/ard.2006.062901 CrossRefPubMedPubMedCentral

12.

Denton CP, Black CM (2004) Scleroderma–clinical and pathological advances. Best Pract Res Clin Rheumatol 18(3):271–290. https://doi.org/10.1016/j.berh.2004.03.001 CrossRefPubMed

13.

Helfrich DJ, Banner B, Steen VD, Medsger TA Jr (1989) Normotensive renal failure in systemic sclerosis. Arthritis Rheum 32(9):1128–1134CrossRefPubMed

14.

Pham PT, Pham PC, Danovitch GM, Gritsch HA, Singer J, Wallace WD, Hayashi R, Wilkinson AH (2005) Predictors and risk factors for recurrent scleroderma renal crisis in the kidney allograft: case report and review of the literature. Am J Transplant 5(10):2565–2569. https://doi.org/10.1111/j.1600-6143.2005.01035.x CrossRefPubMed

15.

Kuwana M, Okano Y, Pandey JP, Silver RM, Fertig N, Medsger TA Jr (2005) Enzyme-linked immunosorbent assay for detection of anti-RNA polymerase III antibody: analytical accuracy and clinical associations in systemic sclerosis. Arthritis Rheum 52(8):2425–2432. https://doi.org/10.1002/art.21232 CrossRefPubMed

16.

Dore A, Lucas M, Ivanco D, Medsger TA Jr, Domsic RT (2013) Significance of palpable tendon friction rubs in early diffuse cutaneous systemic sclerosis. Arthritis Care Res (Hoboken) 65(8):1385–1389. https://doi.org/10.1002/acr.21964 CrossRef

17.

Steen VD, Medsger TA Jr (1998) Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 41(9):1613–1619. https://doi.org/10.1002/1529-0131(199809)41:9%3c1613:AID-ART11%3e3.0.CO;2-O CrossRefPubMed

18.

Teixeira L, Mouthon L, Mahr A, Berezne A, Agard C, Mehrenberger M, Noel LH, Trolliet P, Frances C, Cabane J, Guillevin L, Group Francais de Recherche sur le S (2008) Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients. Ann Rheum Dis 67(1):110–116. https://doi.org/10.1136/ard.2006.066985 CrossRef

19.

Guillevin L, Berezne A, Seror R, Teixeira L, Pourrat J, Mahr A, Hachulla E, Agard C, Cabane J, Vanhille P, Harle JR, Deleveaux I, Mouthon L (2012) Scleroderma renal crisis: a retrospective multicentre study on 91 patients and 427 controls. Rheumatology (Oxford) 51(3):460–467. https://doi.org/10.1093/rheumatology/ker271 CrossRef

20.

Stern E, Steen V, Denton C (2015) Management of renal involvement in scleroderma. Curr Treat Opt Rheumatology 1(1):106–118CrossRef

21.

Traub YM, Shapiro AP, Rodnan GP, Medsger TA, McDonald RH, Jr., Steen VD, Osial TA, Jr., Tolchin SF (1983) Hypertension and renal failure (scleroderma renal crisis) in progressive systemic sclerosis. Review of a 25-year experience with 68 cases. Medicine (Baltimore) 62(6):335–352

22.

Mouthon L, Bussone G, Berezne A, Noel LH, Guillevin L (2014) Scleroderma renal crisis. J Rheumatol 41(6):1040–1048. https://doi.org/10.3899/jrheum.131210 CrossRefPubMed

23.

Bhangoo MS, Hein P, Nicholson L, Carter C (2014) Spontaneous subdural haemorrhage in a patient with scleroderma renal crisis. BMJ Case Rep 2014. https://doi.org/10.1136/bcr-2014-205471 CrossRefPubMedPubMedCentral

24.

Vaughan JH, Shaw PX, Nguyen MD, Medsger TA Jr, Wright TM, Metcalf JS, Leroy EC (2000) Evidence of activation of 2 herpesviruses, Epstein–Barr virus and cytomegalovirus, in systemic sclerosis and normal skins. J Rheumatol 27(3):821–823PubMed

25.

Appenzeller S, Montenegro MA, Dertkigil SS, Sampaio-Barros PD, Marques-Neto JF, Samara AM, Andermann F, Cendes F (2004) Neuroimaging findings in scleroderma en coup de sabre. Neurology 62(9):1585–1589CrossRefPubMed

26.

Bose N, Chiesa-Vottero A, Chatterjee S (2015) Scleroderma renal crisis. Semin Arthritis Rheum 44(6):687–694. https://doi.org/10.1016/j.semarthrit.2014.12.001 CrossRefPubMed

27.

Cisse MM, Seck SM, Oumar DA, Fall K, Lemrabott AT, Diallo M, Faye M, Faye M, Niang A, Diouf B (2015) Scleroderma renal crisis in tropical region: two senegalese cases. Pan Afr Med J 21:46. https://doi.org/10.11604/pamj.2015.21.46.6344 CrossRefPubMedPubMedCentral

28.

Fisher ER, Rodnan GP (1958) Pathologic observations concerning the kidney in progressive systemic sclerosis. AMA Arch Pathol 65(1):29–39PubMed

29.

Steen VD, Mayes MD, Merkel PA (2003) Assessment of kidney involvement. Clin Exp Rheumatol 21(3 Suppl 29):S29–31PubMed

30.

DeMarco PJ, Weisman MH, Seibold JR, Furst DE, Wong WK, Hurwitz EL, Mayes M, White B, Wigley F, Barr W, Moreland L, Medsger TA Jr, Steen V, Martin RW, Collier D, Weinstein A, Lally E, Varga J, Weiner SR, Andrews B, Abeles M, Clements PJ (2002) Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum 46(11):2983–2989. https://doi.org/10.1002/art.10589 CrossRefPubMed

31.

Steen VD, Medsger TA Jr (1997) The palpable tendon friction rub: an important physical examination finding in patients with systemic sclerosis. Arthritis Rheum 40(6):1146–1151. https://doi.org/10.1002/1529-0131(199706)40:6%3c1146:AID-ART19%3e3.0.CO;2-9 CrossRefPubMed

32.

Randone SB, Guiducci S, Cerinic MM (2008) Musculoskeletal involvement in systemic sclerosis. Best Pract Res Clin Rheumatol 22(2):339–350. https://doi.org/10.1016/j.berh.2008.01.008 CrossRefPubMed

33.

Molina JF, Anaya JM, Cabrera GE, Hoffman E, Espinoza LR (1995) Systemic sclerosis sine scleroderma: an unusual presentation in scleroderma renal crisis. J Rheumatol 22(3):557–560PubMed

34.

Gonzalez EA, Schmulbach E, Bastani B (1994) Scleroderma renal crisis with minimal skin involvement and no serologic evidence of systemic sclerosis. Am J Kidney Dis 23(2):317–319CrossRefPubMed

35.

Bussone G, Noel LH, Mouthon L (2011) Renal involvement in patients with systemic sclerosis. Nephrol Ther 7(3):192–199. https://doi.org/10.1016/j.nephro.2011.03.006 CrossRefPubMed

36.

Morris K, Connolly JO, O'Donnell PJ, Scoble JE (1994) Malignant hypertension and renal failure: scleroderma renal crisis or renal artery stenosis? Nephrol Dial Transplant 9(10):1489–1491PubMed

37.

Haluszka O, Rabetoy GM, Mosley CA, Duke MS (1989) Bilateral renal artery stenosis: presenting as a case of scleroderma renal crisis. Clin Nephrol 32(6):262–265PubMed

38.

Keeler E, Fioravanti G, Samuel B, Longo S (2015) Scleroderma renal crisis or thrombotic thrombocytopenic purpura: seeing through the masquerade. Lab Med 46(2):e39–44. https://doi.org/10.1309/LM72AM5XFHZYOQCB CrossRefPubMed

39.

Abudiab M, Krause ML, Fidler ME, Nath KA, Norby SM (2013) Differentiating scleroderma renal crisis from other causes of thrombotic microangiopathy in a postpartum patient. Clin Nephrol 80(4):293–297. https://doi.org/10.5414/CN107465 CrossRefPubMed

40.

Loirat C, Fremeaux-Bacchi V (2011) Atypical hemolytic uremic syndrome. Orphanet J Rare Dis 6:60. https://doi.org/10.1186/1750-1172-6-60 CrossRefPubMedPubMedCentral

41.

Coppo P, Veyradier A (2012) Current management and therapeutical perspectives in thrombotic thrombocytopenic purpura. Presse Med 41(3 Pt 2):e163–176. https://doi.org/10.1016/j.lpm.2011.10.024 CrossRefPubMed

42.

Lian EC (2005) Pathogenesis of thrombotic thrombocytopenic purpura: ADAMTS13 deficiency and beyond. Semin Thromb Hemost 31(6):625–632. https://doi.org/10.1055/s-2005-925468 CrossRefPubMed

43.

Manadan AM, Harris C, Block JA (2005) Thrombotic thrombocytopenic purpura in the setting of systemic sclerosis. Semin Arthritis Rheum 34(4):683–688. https://doi.org/10.1016/j.semarthrit.2004.08.008 CrossRefPubMed

44.

Kapur A, Ballou SP, Renston JP, Luna E, Chung-Park M (1997) Recurrent acute scleroderma renal crisis complicated by thrombotic thrombocytopenic purpura. J Rheumatol 24(12):2469–2472PubMed

45.

Yusin J, Lewin K, Clements P (2001) Thrombotic thrombocytopenia purpura in a patient with systemic sclerosis. J Clin Rheumatol 7(2):106–111CrossRefPubMed

46.

Akimoto S, Ishikawa O, Tamura T, Miyachi Y (1996) Antineutrophil cytoplasmic autoantibodies in patients with systemic sclerosis. Br J Dermatol 134(3):407–410CrossRefPubMed

47.

Kao L, Weyand C (2010) Vasculitis in systemic sclerosis. Int J Rheumatol 2010:385938. https://doi.org/10.1155/2010/385938 CrossRefPubMedPubMedCentral

48.

Chan PT, Mok CC (2012) Pauci-immune crescentic glomerulonephritis in limited cutaneous systemic sclerosis. Clin Rheumatol 31(8):1273–1277. https://doi.org/10.1007/s10067-012-2010-8 CrossRefPubMed

49.

Harashima S, Yoshizawa S, Horiuchi T, Nakashima H, Niho Y, Kusaba T, Hayashida I, Shinozaki M, Katafuchi R, Hirakata H (1999) A case of systemic sclerosis with crescentic glomerulonephritis associated with perinuclear-antineutrophil cytoplasmic antibody (p-ANCA). Nihon Rinsho Meneki Gakkai Kaishi 22(2):86–92CrossRefPubMed

50.

Tomioka M, Hinoshita F, Miyauchi N, Akiyama Y, Saima S, Hiroe M (2004) ANCA-related crescentic glomerulonephritis in a patient with scleroderma without marked dermatological change and malignant hypertension. Intern Med 43(6):496–502CrossRefPubMed

51.

Quemeneur T, Mouthon L, Cacoub P, Meyer O, Michon-Pasturel U, Vanhille P, Hatron PY, Guillevin L, Hachulla E (2013) Systemic vasculitis during the course of systemic sclerosis: report of 12 cases and review of the literature. Medicine (Baltimore) 92(1):1–9. https://doi.org/10.1097/MD.0b013e31827781fd CrossRef

52.

Arad U, Balbir-Gurman A, Doenyas-Barak K, Amit-Vazina M, Caspi D, Elkayam O (2011) Anti-neutrophil antibody associated vasculitis in systemic sclerosis. Semin Arthritis Rheum 41(2):223–229. https://doi.org/10.1016/j.semarthrit.2010.11.001 CrossRefPubMed

53.

Rho YH, Choi SJ, Lee YH, Ji JD, Song GG (2006) Scleroderma associated with ANCA-associated vasculitis. Rheumatol Int 26(5):369–375. https://doi.org/10.1007/s00296-005-0011-5 CrossRefPubMed

54.

Derrett-Smith EC, Nihtyanova SI, Harvey J, Salama AD, Denton CP (2013) Revisiting ANCA-associated vasculitis in systemic sclerosis: clinical, serological and immunogenetic factors. Rheumatology (Oxford) 52(10):1824–1831. https://doi.org/10.1093/rheumatology/ket213 CrossRef

55.

Donohoe JF (1992) Scleroderma and the kidney. Kidney Int 41(2):462–477CrossRefPubMed

56.

Zand L, Specks U, Sethi S, Fervenza FC (2014) Treatment of ANCA-associated vasculitis: new therapies and a look at old entities. Adv Chronic Kidney Dis 21(2):182–193. https://doi.org/10.1053/j.ackd.2014.01.009 CrossRefPubMed

57.

Lam M, Ballou SP (1992) Reversible scleroderma renal crisis after cocaine use. N Engl J Med 326(21):1435. https://doi.org/10.1056/NEJM199205213262117 CrossRefPubMed

58.

Denton CP, Sweny P, Abdulla A, Black CM (1994) Acute renal failure occurring in scleroderma treated with cyclosporin A: a report of three cases. Br J Rheumatol 33(1):90–92CrossRefPubMed

59.

Hamaguchi Y, Kodera M, Matsushita T, Hasegawa M, Inaba Y, Usuda T, Kuwana M, Takehara K, Fujimoto M (2015) Clinical and immunologic predictors of scleroderma renal crisis in Japanese systemic sclerosis patients with anti-RNA polymerase III autoantibodies. Arthritis Rheumatol 67(4):1045–1052. https://doi.org/10.1002/art.38994 CrossRefPubMed

60.

Rosato E, Gigante A, Barbano B, Cianci R, Molinaro I, Rossi C, Massa R, Amoroso A, Pisarri S, Salsano F (2012) Intrarenal hemodynamic parameters correlate with glomerular filtration rate and digital microvascular damage in patients with systemic sclerosis. Semin Arthritis Rheum 41(6):815–821. https://doi.org/10.1016/j.semarthrit.2011.11.005 CrossRefPubMed

61.

Steen VD, Medsger TA Jr (2000) Long-term outcomes of scleroderma renal crisis. Ann Intern Med 133(8):600–603CrossRefPubMed

62.

Steen VD, Costantino JP, Shapiro AP, Medsger TA Jr (1990) Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 113(5):352–357CrossRefPubMed

63.

Kowal-Bielecka O, Landewe R, Avouac J, Chwiesko S, Miniati I, Czirjak L, Clements P, Denton C, Farge D, Fligelstone K, Foldvari I, Furst DE, Muller-Ladner U, Seibold J, Silver RM, Takehara K, Toth BG, Tyndall A, Valentini G, van den Hoogen F, Wigley F, Zulian F, Matucci-Cerinic M, Co-Authors E (2009) EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 68(5):620–628. https://doi.org/10.1136/ard.2008.096677 CrossRefPubMed

64.

Vaughan CJ, Delanty N (2000) Hypertensive emergencies. Lancet 356(9227):411–417. https://doi.org/10.1016/S0140-6736(00)02539-3 CrossRefPubMed

65.

Varga J, Denton C, Wigley F, Allanore Y, Kuwana M (2017) Scleroderma: from pathogenesis to comprehensive management.

66.

Thurm RH, Alexander JC (1984) Captopril in the treatment of scleroderma renal crisis. Arch Intern Med 144(4):733–735CrossRefPubMed

67.

Caskey FJ, Thacker EJ, Johnston PA, Barnes JN (1997) Failure of losartan to control blood pressure in scleroderma renal crisis. Lancet 349(9052):620CrossRefPubMed

68.

Cheung WY, Gibson IW, Rush D, Jeffery J, Karpinski M (2005) Late recurrence of scleroderma renal crisis in a renal transplant recipient despite angiotensin II blockade. Am J Kidney Dis 45(5):930–934CrossRefPubMed

69.

Walker KM, Pope J, participating members of the Scleroderma Clinical Trials C, Canadian Scleroderma Research G (2012) Treatment of systemic sclerosis complications: what to use when first-line treatment fails–a consensus of systemic sclerosis experts. Semin Arthritis Rheum 42(1):42–55. https://doi.org/10.1016/j.semarthrit.2012.01.003 CrossRef

70.

Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G, Silman A (2000) Prazosin for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev (2):CD000956. https://doi.org/ https://doi.org/10.1002/14651858.CD000956

71.

Mohokum M, Hartmann P, Schlattmann P (2012) The association of Raynaud syndrome with beta-blockers: a meta-analysis. Angiology 63(7):535–540. https://doi.org/10.1177/0003319711432861 CrossRefPubMed

72.

Penn H, Quillinan N, Khan K, Chakravarty K, Ong VH, Burns A, Denton CP (2013) Targeting the endothelin axis in scleroderma renal crisis: rationale and feasibility. QJM 106(9):839–848. https://doi.org/10.1093/qjmed/hct111 CrossRefPubMed

73.

Woodworth TG, Suliman YA, Li W, Furst DE, Clements P (2018) Scleroderma renal crisis and renal involvement in systemic sclerosis. Nat Rev Nephrol 14(2):137. https://doi.org/10.1038/nrneph.2017.183 CrossRefPubMed

74.

Tulman DB, Stawicki SP, Papadimos TJ, Murphy CV, Bergese SD (2012) Advances in management of acute hypertension: a concise review. Discov Med 13(72):375–383PubMedPubMedCentral

75.

Rivera A, Montoya E, Varon J (2010) Intravenous clevidipine for management of hypertension. Integr Blood Press Control 3:105–111PubMedPubMedCentral

76.

Robson M, Oreopoulos DG (1978) Dialysis in scleroderma. Ann Intern Med 88(6):843CrossRefPubMed

77.

Copley JB, Smith BJ (1985) Continuous ambulatory peritoneal dialysis and scleroderma. Nephron 40(3):353–356. https://doi.org/10.1159/000183492 CrossRefPubMed

78.

Bertrand D, Dehay J, Ott J, Sberro R, Brunelle C, Kamar N, Colosio C, Chatelet V, Albano L, Girerd S, Audard V, Barbet C, Dantal J, Ducloux D, Durrbach A, Garrigue V, Hazzan M, Heng AE, Mariat C, Merville P, Rerolle JP, Moulin B, Guerrot D (2017) Kidney transplantation in patients with systemic sclerosis: a nationwide multicentre study. Transpl Int 30(3):256–265. https://doi.org/10.1111/tri.12923 CrossRefPubMed

79.

Clements PJ, Seibold JR, Furst DE, Mayes M, White B, Wigley F, Weisman MD, Barr W, Moreland L, Medsger TA Jr, Steen V, Martin RW, Collier D, Weinstein A, Lally E, Varga J, Weiner SR, Andrews B, Abeles M, Wong WK (2004) High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learned. Semin Arthritis Rheum 33(4):249–263CrossRefPubMed

80.

Furst DE, Clements PJ (2001) D-penicillamine is not an effective treatment in systemic sclerosis. Scand J Rheumatol 30(4):189–191CrossRefPubMed

81.

Young A, Khanna D (2015) Systemic sclerosis: a systematic review on therapeutic management from 2011 to 2014. Curr Opin Rheumatol 27(3):241–248. https://doi.org/10.1097/BOR.0000000000000172 CrossRefPubMedPubMedCentral

82.

Lynch BM, Stern EP, Ong V, Harber M, Burns A, Denton CP (2016) UK Scleroderma Study Group (UKSSG) guidelines on the diagnosis and management of scleroderma renal crisis. Clin Exp Rheumatol 34(5):106–109

Titel: Scleroderma renal crisis: a review for emergency physicians
Publikationsdatum: 10.05.2019
Erschienen in: Internal and Emergency Medicine / Ausgabe 4/2019
Print ISSN: 1828-0447
Elektronische ISSN: 1970-9366
DOI: https://doi.org/10.1007/s11739-019-02096-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Scleroderma renal crisis: a review for emergency physicians

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2019

SIRS or qSOFA? Is that the question? Clinical and methodological observations from a meta-analysis and critical review on the prognostication of patients with suspected sepsis outside the ICU

Central PRES (posterior reversible encephalopathy syndrome) in HELLP syndrome

Retroperitoneal dedifferentiated liposarcoma

Prevalence of antiphospholipid antibodies among patients with chronic thromboembolic pulmonary hypertension

Prevalence and outcome of diuretic resistance in heart failure

Symptom expression in advanced cancer patients admitted to hospice or home care with and without delirium

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin